We are submitting herewith the monitoring agency report

Kilitch Drugs (India) Ltd. 17" August, 2026 To, To, The Manager - Corporate Relationship The Manager - Corporate Compliance Dept. National Stock Exchange of India Ltd BSE Limited Exchange Plaza, Plot No.C-1, P. J. Towers, Dalal Street G Block, BKC, Bandra (E), Fort, Mumbai - 400 001 Mumbai 400 051 Scrip Code: BSE - 524500 Scrip Code: NSE - KILITCH Sub: Disclosure under Regulation 32 of the SEBI (Listing Obligations and _ Disclosure Requirements) Regulations, 2015 - Monitoring Agency Report for the quarter ended 30% June, 2026. Dear Sir, Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith the Monitoring Agency Report dated 17" August, 2026, issued by Infomerics Valuation and Rating Limited, Monitoring Agency, for the quarter ended 30" June, 2026 This disclosure will also be hosted on the Company's website viz: www.kilitch.com Request you to kindly take note of the same and acknowledge the receipt. Thanking you, Yours’ Faithfully, For Kilitch Drugs (India) Limited Mukund Mehta Managing Director DIN: 00147876 haIse SOstats) et e GGe3e )N y A 4 INDIA 43485-2003 WHO CERTIFIED haroah kwyo Corporate office : 37/39, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088. « Tel.: +91-22-6121 4100 « Fax : +91-22-6703 1658 Registered Office & Manufacturing unit : C-301/2, M.1.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra. « CIN: L24239MH1992PLC066718 « Tel.: +91-22-6299 6300 « Fax : +91-22-2768 0912 « E-mail : info@kilitch.com « Website : www.kilitch.com e © ® Infomerics Ratings of )@ Sf 8) REGHTERLD / AB) ACCREDITED / NSIC ry @ MPARUAEG CI Monitoring Agency Report for Kilitch Drugs (India) Limited for the quarter ended June 30, 2026 ® @ © Infomerics Ratings CID® sipinces @ee MPANLLLED CREDIT HATING AGENCY Monitoring Agency Report August 17, 2026 Kilitch Drugs (India) Limited C-301/2 MIDC, TIC Industrial Area, Pawane Village. ‘Thane, Maharashtra, India, 400705, Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Right Issue of Kilitch Drugs (India) Limited (“The Company”) We write in our capacity of Monitoring Agency for the Right issue of equity shares for the amount aggregating to Rs. 49.92 crore of the Company and refer to our duties cast under 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations). In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated 02 July 2025. Request you to kindly take the same on records. Thanking you, For and on behof aInflomefric s Valuation and Rating Limited Sudarshan Shreenivas (Director- Ratings) sudarshan.shreenivas(@infomerics.com @ 0e ea eae Report of the Monitoring Agency Name of the Issuer: Kilitch Drugs (India) Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Infomerics Valuation and Rating Limited (a) Deviation from the objects: No Deviation (b) Range of Deviation: Not Applicable Indicate range of percentage deviation from the amount of issue proceeds earmarked for objects. For example. up to 10%, 10 — 25%, 25-50%, 50-75%, 75-100%, not ascertainable etc. * Range of Deviation may be computed by taking weighted average of financial deviation of each object in the ratio of issue proceeds allocated for it. Non-financial deviation may be indicated separately by way of notes. Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. Irifomerics Ratings CONT RATING AGEN We declare that we do not have any direct / indirect interest in or relationship with the issucr/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer. We further declare that this report provides true and fair view of the utilization of issue procecds. Siie gnature: a Name of the Authorized Person/Signing Authority: Sudarshan Shreenivas Designation of Authorized person/Signing Autherity: Director- Ratings Seal of the Monitoring Agency: Date: August 17, 2026 s g n i t a r e m o f n ® ef ran ienc arketing ecades aggregating and three 47.00) lyi ove Rs. th of ing, lobe emium r g r actu Limited tical manuf ntal across (including (Pharma armaceu Pare Kilitch Comp ently engaged like Solid, Note issue cast © 6 )D se st ua ei rl s: Name of issuer: Kilitch Drugs (India) Limited Names promoters issuer: Mukund Mehta Industry/sector to which belongs: Company pres pharmaceutical formulations various dosage forms Issue Details: Issue Period: July 2025, August 2025 Typeo f issue( public/rightsR )i htsI ssue Type of specified securities: Rights Equity shares GraN np gp :l icable Issue size Crores): 49.92 crores (Note Note | Q2FY26, company issued 13.98.463 Equity Shares .erorc ?9.94 \% 6 OO t a R s c i r e m o f n I etoN u u s s s s i i s of d towa lance a d b crore) utilize crore, Prospectus 49.92 0.47* .45** hese 1.08 crore estimated at 0.47 during Q2FY was oses O es rp t s u n . n P mou 026 expe A 2 a Y r Q2F related Corpo n l duri issue nera issue ards rights tow object pect s m o r o r e fr p nd Particulars Received from Right Issue ated Expenses vailable Utilization company received 49.92 cror nses. However, since allocation nsesi .e. 0.61 crore were utilized l A e e Proceeds Issue Proceeds Note: related related oe e TL N : s d e e c u s s i r o s t d i e n e o oc m he su tus ing to e o e p t d ros oni ma er be shall rangem n g r e n a p i ex Rat he ted cs of t ssue rela Intfomeri Details “I ** s of rs t o ommen Board Direct o My c of en s Ag t n Source of information / rtifications considered b Monitoring Agency preparation report y l p e R s r a l u c i t r a P b a c i l e t o r e f e R Prospectu laration Statement, Invoices, ement g Bank cate*, mana rtifi s e Y u s o s i d ation is Offer cument? liz Do i t u all r e t e h W : nexccae srecnad eniica gnirna tpec oreesarec @ @ @ a c in es r d u e t n i al is obtai ex rp oe mn d Offer approv f ions in sed older deviat disclo h e l r a Sha teri a m her of t e h W stnemmoC si erehT .noitaived lairetam deriuqer ecneH ?tnemucoD e l b a c i l p p A t o N ?degnahc sah eussI s t c e j b o d e s o l c s i d for e c n a n i f s n a e m r e h t e h W egnahc on si erehT ecnanif fo snaem e l b a c i l p p A t o N elbacilppA elbacilppA elbacilppA reilrae eht revo devresbo noitaived rojam ?stroper ycnega gnirotinom e l b a c i l p p A t o N s l a v o r p p ? a d tutory obtaine Sta s) / t( c nt bje e o nm [Showing first 8,000 characters — download PDF for full document]